Harbor Capital Advisors Inc. Trims Stake in LeMaitre Vascular, Inc. $LMAT

Harbor Capital Advisors Inc. cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 70.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,512 shares of the medical instruments supplier’s stock after selling 15,770 shares during the period. Harbor Capital Advisors Inc.’s holdings in LeMaitre Vascular were worth $570,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of LMAT. Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after purchasing an additional 18,298 shares during the period. Ausbil Investment Management Ltd increased its position in LeMaitre Vascular by 15.5% in the third quarter. Ausbil Investment Management Ltd now owns 2,532 shares of the medical instruments supplier’s stock worth $219,000 after buying an additional 339 shares in the last quarter. Public Sector Pension Investment Board raised its stake in shares of LeMaitre Vascular by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 70,119 shares of the medical instruments supplier’s stock worth $5,823,000 after buying an additional 5,190 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of LeMaitre Vascular by 398.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,736 shares of the medical instruments supplier’s stock valued at $144,000 after buying an additional 1,388 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in shares of LeMaitre Vascular by 149.4% during the 2nd quarter. Captrust Financial Advisors now owns 9,446 shares of the medical instruments supplier’s stock valued at $784,000 after acquiring an additional 5,659 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 0.7%

Shares of NASDAQ LMAT opened at $83.78 on Monday. The business’s 50 day moving average is $86.00 and its two-hundred day moving average is $87.30. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $105.55. The stock has a market capitalization of $1.90 billion, a P/E ratio of 36.11, a PEG ratio of 2.07 and a beta of 0.68. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. During the same quarter in the previous year, the business posted $0.49 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio is presently 34.48%.

Analysts Set New Price Targets

A number of equities research analysts have commented on LMAT shares. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Barrington Research reaffirmed an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Wells Fargo & Company decreased their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.